S.A. Mason’s Viking Therapeutics VKTX Stock Holding History

S.A. Mason’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,900	Closed	-$102K	–	277
2025 Q4	$102K	Buy	+2,900	New	+$103K	0.04%	259
2025 Q3	–	Sell	-1,800	Closed	-$47.7K	–	357
2025 Q2	$47.7K	Hold	1,800	–	–	0.02%	289
2025 Q1	$43.5K	Hold	1,800	–	–	0.02%	281
2024 Q4	$72.4K	Buy	1,800 +300	+20%	+$17.1K	0.04%	251
2024 Q3	$95K	Sell	1,500 -100	-6%	-$5.87K	0.05%	232
2024 Q2	$84.8K	Buy	+1,600	New	+$105K	0.05%	226

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

S.A. Mason's VKTX Position: Q1 2026 in Review

S.A. Mason sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 2,900 shares — an estimated $102K sold.

S.A. Mason first reported a position in VKTX in Q2 2024 and held it in 6 quarters. The position peaked at $102K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

S.A. Mason reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
S.A. Mason sold 2,900 Viking Therapeutics shares in Q1 2026, an estimated $102K.
S.A. Mason first reported a position in Viking Therapeutics in Q2 2024 and held it in 6 quarters.
S.A. Mason's Viking Therapeutics position peaked at $102K in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on S.A. Mason's 13F filing for Q1 2026, filed 27 Apr 2026.